PTN

Business Context and Reporting Period

Company: Palatin Technologies, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2011
Business Overview: Palatin is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics. Its primary focus is bremelanotide for female sexual dysfunction (FSD), currently in Phase 2B clinical trials. The company also develops PL-3994 for acute asthma, heart failure, and hypertension, and maintains a collaboration with AstraZeneca for obesity treatments (AZD2820). The company has never been profitable and relies on financing and collaboration revenue to fund operations.

Key Financial Metrics

Note: Revenue in 2011 included $0.98 million in federal grants and $0.50 million in reimbursement from AstraZeneca. Revenue in 2010 was significantly higher due to the recognition of remaining deferred up-front license fees from AstraZeneca.

Material Changes vs. Prior Period

• Revenue Decline: Revenue dropped 89.6% year-over-year, primarily because the company recognized the final portion of its AstraZeneca up-front license fee in 2010, which was not repeated in 2011.
• Increased Net Loss: Net loss widened significantly from $1.79 million to $12.82 million, driven by the sharp decline in revenue and continued operating expenses.
• Capital Raise: In March 2011, the company completed a public offering of 23 million units (stock and warrants) at $1.00 per unit, generating net proceeds of approximately $21.0 million. This increased cash balances from $5.4 million to $18.9 million.
• Expense Reduction: R&D expenses decreased by $1.9 million and G&A expenses decreased slightly, reflecting a strategic decision in September 2010 to reduce staffing and focus resources on bremelanotide and PL-3994.

Guidance, Outlook, and Risks

Outlook and Liquidity: Management believes current cash resources ($18.9 million) are sufficient to fund planned operations, including the completion of the Phase 2B bremelanotide trial, through at least calendar year 2012. However, funds are insufficient to complete all required clinical trials for product approval. Phase 3 trials for bremelanotide are not expected to commence before 2013 and will require significant additional capital.

Strategic Focus: The company has suspended research on new product candidates and is focusing exclusively on bremelanotide (FSD) and limited development of PL-3994 (asthma/heart failure). Further development of PL-3994 or new candidates is contingent on securing additional capital or partnerships.

Key Risks:

• Need for Additional Funding: The company must raise additional funds to proceed with Phase 3 trials or risk curtailing operations.
• Regulatory Approval: No products are approved. Success depends on FDA approval, which is uncertain. Previous trials with intranasal bremelanotide were discontinued due to blood pressure side effects; current subcutaneous trials aim to mitigate this.
• Collaboration Dependency: Future revenue from the AstraZeneca agreement is limited to reimbursements and potential milestones, as the active research collaboration portion concluded in January 2010.
• Dilution: Significant dilution exists due to outstanding warrants (24.4 million shares) and options (2.2 million shares).

Investor Verification Checklist

• Cash Runway: Verify if the $18.9 million cash balance is sufficient to complete the Phase 2B bremelanotide trial without further dilution or partnership deals before 2012.
• Phase 2B Results: Monitor the anticipated results of the bremelanotide Phase 2B trial (expected H2 2012) for safety (blood pressure) and efficacy data.
• Financing Plans: Assess the company's strategy for raising capital for Phase 3 trials, which are projected to start no earlier than 2013.
• Dilution Impact: Review the terms of the 24.4 million outstanding warrants (many exercisable at $1.00) and their potential impact on share price and ownership.
• AstraZeneca Milestones: Track the development of AZD2820 by AstraZeneca to determine if any milestone payments are triggered.